{"contentid": 488769, "importid": NaN, "name": "FDA nod for Biohaven's Nurtec ODT for migraine prevention", "introduction": "The US Food and Drug Administration has approved Nurtec ODT (rimegepant 75mg) for the preventive treatment of migraine, thus the drug becomes the first oral CGRP antagonist option to both prevent and treat migraines.", "content": "<p>The US Food and Drug Administration has approved Nurtec ODT (rimegepant 75mg) for the preventive treatment of migraine, thus the drug becomes the first oral CGRP antagonist option to both prevent and treat migraines. Nurtec ODT is indicated for adult patients with episodic migraine, eg, those who experience less than 15 headache days per month.</p>\n<p>The news sent shares of the drug&rsquo;s developer, Biohaven Pharmaceutical (NYSE: BHVN) up 3% to $85.00 in after-hours trading on Thursday.</p>\n<p>The FDA first approved Biohaven&rsquo;s Nurtec ODT for the acute treatment of migraine in adults. In February last year. Total revenues from Nurtec ODT were $43.8 million in the first quarter 2021, up around 24.8% sequentially. Revenues were in line with the Zacks Consensus Estimate.&nbsp;</p>\n<p>Total revenues from Nurtec ODT were $43.8 million in the first quarter, up almost 24.8% sequentially, and in line with the Zacks Consensus Estimate.</p>\n<p>The approved product label was also expanded to include the use of Nurtec ODT 75mg up to 18 doses/month, allowing for both acute and preventive therapy in the same patient. This new approval makes Nurtec ODT the first oral CGRP antagonist approved for the preventive treatment of migraine, and the only migraine medication approved as a dual therapy for both the acute and preventive treatment. Nurtec ODT is approved for acute treatment in all eligible adult patients with migraine, regardless of the number of monthly migraine days.</p>\n<h2><strong>New indication significantly expands the market potential</strong></h2>\n<p>Since approximately 95% of all US migraine patients experience less than 15 headache days per month, the new indication of preventive treatment significantly expands the market potential of Nurtec ODT and provides a new preventive treatment option for the vast majority of people living with migraine.</p>\n<p>The migraine space is forecast by GlobalData to be worth up to $9 billion by 2026. This area is mainly occupied by biologics, including Novartis (NOVN: VX) and Amgen&rsquo;s (Nasdaq: AMGN) drug Aimovig (erenumab), Eli Lilly&rsquo;s (NYSE: LLY) Emgality (galcanezumab), Teva Pharmaceutical&rsquo;s (NYSE: TEVA) Ajovy (fremanezumab) and Lundbeck&rsquo;s (LUND: CO) eptinezumab.</p>\n<p>Dr Peter Goadsby, Professor of Neurology at the&nbsp;University of California, Los Angeles and King's College London, recipient of the 2021 Brain Prize for his ground-breaking research discovering the role of CGRP in migraine, and co-author of the Phase III preventive study published in The Lancet, commented, \"The FDA approval of Nurtec ODT for the preventive treatment of migraine - along with its acute treatment indication - is one of the most ground-breaking things to happen to migraine treatment in my 40 years of practicing headache medicine. To have one medication patients can use to treat and prevent migraine will likely change the treatment paradigm for many of the millions of people who live with migraine.\"</p>", "date": "2021-05-28 10:53:00", "meta_title": "FDA nod for Biohaven's Nurtec ODT for migraine prevention", "meta_keywords": "Biohaven Pharmaceutical,  Nurtec ODT, Migraine, Prevention, FDA, Approval", "meta_description": "FDA nod for Biohaven's Nurtec ODT for migraine prevention", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-28 10:51:26", "updated": "2021-05-28 11:01:34", "access": NaN, "url": "https://www.thepharmaletter.com/article/fda-nod-for-biohaven-s-nurtec-odt-for-migraine-prevention", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biohaven_large.jpg", "image2id": "biohaven_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Migraine", "sector_tag": "Pharmaceutical", "therapy area_tag": "Analgesia, Neurological", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Biohaven Pharmaceutical", "drug_tag": "Nurtec ODT", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-28 10:53:00"}